North America Cancer Immunotherapy Market Size & Outlook
Related Markets
North America cancer immunotherapy market highlights
- The North America cancer immunotherapy market generated a revenue of USD 66,304.2 million in 2025.
- The market is expected to grow at a CAGR of 8.3% from 2026 to 2033.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 66,304.2 million |
| Market revenue in 2033 | USD 124,762.5 million |
| Growth rate | 8.3% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 43.3% of the global cancer immunotherapy market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 71,890.9 million by 2033.
Monoclonal antibodies was the largest segment with a revenue share of 63.11% in 2025. Horizon Databook has segmented the North America cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.
High growth of the cancer immunotherapy market in North America can be attributed to various factors, such as rise in burden of cancer and increase in number of favorable government initiatives. Funding for cancer research is high in the region. Moreover, increasing demand for personalized medicines is expected to positively impact growth of the North American cancer immunotherapy market.
Moreover, government regulations in North America support R&D for novel cancer immune therapeutics. Major players operating in this market are Merck & Co., Inc.; Bristol-Myers Squibb Company; and F. Hoffmann-La Roche Ltd. Presence of some of the leading companies is expected to increase availability of cancer immune therapeutics in the region.
For instance, in May 2017, the U.S. FDA approved Keytruda (Merck & Co., Inc.) for cancer patients with certain specific biomarkers. North America holds a major market share, especially the U.S., due to increasing awareness about the potential of immunotherapy and targeted therapy. This factor has driven the U.S.-based firms to make considerable investments in the development of novel drugs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Immunocore Holdings PLC ADR | View profile | 497 | 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY | https://www.immunocore.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
North America cancer immunotherapy market size, by country, 2021-2033 (US$M)
North America Cancer Immunotherapy Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
